Abstracts tagged "rheumatoid arthritis (RA) and utilization review"

Abstract Number: 1041 • 2017 ACR/ARHP Annual Meeting
Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US
Janna Radtchenko, Yolaine Smith, Jonathan Kish and Bruce Feinberg, Specialty Solutions, Cardinal Health, Dallas, TX
Background/Purpose: A biosimilar product is a biological product highly similar to another FDA-approved biological product, reference product, and has no clinically meaningful differences in safety…
Abstract Number: 2331 • 2016 ACR/ARHP Annual Meeting
Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis
Jasvinder A. Singh¹, Bradley Young², Shawna Watson³, jorge perez², Gerald McGwin² and Brent Ponce², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³university of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this study was to analyze time-trends in various types of total joint arthroplasty (TJA) and assess if the proportion of the…
Abstract Number: 1220 • 2016 ACR/ARHP Annual Meeting
Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative
L Rosenblatt¹, K Price¹, Y Doleh¹, A Szymialis¹, M Eaddy², A Ogbonnaya², H-C Shih² and L Lamerato³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Xcenda, LLC, Palm Harbor, FL, ³Henry Ford Health System, Detroit, MI
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody is a marker used in the diagnosis of RA, and it may be useful in identifying patients who are…
Abstract Number: 1226 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
E Alemao¹, Z Guo¹, L Burns¹, M Frits², Jonathan Coblyn², Michael Weinblatt² and NA Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women’s Hospital, Boston, MA
Background/Purpose: The association between inflammatory markers such as CRP or ESR and joint damage has been widely established in RA. Autoantibodies such as RF and…
Abstract Number: 2725 • 2015 ACR/ARHP Annual Meeting
Secular Trends in Use of Disease Modifying Anti-Rheumatic Drugs for the Treatment of Rheumatoid Arthritis in the United States
Rishi J. Desai¹, Daniel H. Solomon², Jun Liu³ and Seoyoung C. Kim⁴, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Treatment of rheumatoid arthritis (RA) with disease modifying anti-rheumatic drugs (DMARDs) has undergone major advances in last two decades. More than 10 non-biologic DMARDs…
Abstract Number: 2278 • 2013 ACR/ARHP Annual Meeting
Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers: Under-Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists
Emily H. Glynn¹, Mark H. Wener² and Michael Astion³, ¹Laboratory Medicine, University of Washington, Seattle, WA, ²Rheumatology & Lab Med, University of Washington, Seattle, WA, ³Department of Laboratories, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Anti-citrullinated peptide antibodies (ACPA) are more specific and have a superior positive predictive value for diagnosis of rheumatoid arthritis (RA) compared to RF. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].